GLP-1 receptor agonists in the treatment of T2DM
At least six oral and two injectable medication classes are available as therapeutic options in Australia
According to Australian Institute of Health and Welfare data from 2017-18, approximately 5% of Australians have diabetes, and the condition accounts for 1.2 million hospitalisations annually.1
More than 90% of those with diabetes have type 2 diabetes. At least six oral and two injectable medication classes are available as therapeutic options in Australia (see box 1).2
Choosing an optimal agent or combination can sometimes be challenging.3 This review will focus on the role of glucagon-like peptide-1 receptor agonists.
Oral
